350 related articles for article (PubMed ID: 15722065)
1. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
Beksinska ME; Smit JA; Kleinschmidt I; Farley TM; Mbatha F
Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065
[TBL] [Abstract][Full Text] [Related]
2. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception.
Beksinska ME; Kleinschmidt I; Smit JA; Farley TM
Contraception; 2007 Jun; 75(6):438-43. PubMed ID: 17519149
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study.
Pongsatha S; Ekmahachai M; Chaovisitsaree S; Suntornlimsiri N; Morakote N
J Med Assoc Thai; 2009 Oct; 92(10):1263-7. PubMed ID: 19845231
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density and depot medroxyprogesterone acetate.
Albertazzi P; Bottazzi M; Steel SA
Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487
[TBL] [Abstract][Full Text] [Related]
6. Effects of hormonal contraception on bone mineral density after 24 months of use.
Berenson AB; Breitkopf CR; Grady JJ; Rickert VI; Thomas A
Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in midlife long-term users of hormonal contraception in South Africa: relationship with obesity and menopausal status.
Beksinska ME; Kleinschmidt I; Smit JA
Womens Midlife Health; 2018; 4():6. PubMed ID: 30766716
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate.
Beksinska ME; Kleinschmidt I; Smit JA; Farley TM
Contraception; 2009 May; 79(5):345-9. PubMed ID: 19341845
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.
Clark MK; Sowers MR; Nichols S; Levy B
Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives.
Bahamondes L; Juliato CT; Villarreal M; Sobreira-Lima B; Simões JA; dos Santos Fernandes AM
Contraception; 2006 Sep; 74(3):259-63. PubMed ID: 16904421
[TBL] [Abstract][Full Text] [Related]
11. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.
Shaarawy M; El-Mallah SY; Seoudi S; Hassan M; Mohsen IA
Contraception; 2006 Oct; 74(4):297-302. PubMed ID: 16982229
[TBL] [Abstract][Full Text] [Related]
12. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
Arch Pediatr Adolesc Med; 2005 Feb; 159(2):139-44. PubMed ID: 15699307
[TBL] [Abstract][Full Text] [Related]
13. Assessing menopausal status in women aged 40 - 49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception.
Beksinska ME; Smit JA; Kleinschmidt I; Farley TM
S Afr Med J; 2011 Feb; 101(2):131-5. PubMed ID: 21678742
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density in adolescent females using depot medroxyprogesterone acetate.
Lara-Torre E; Edwards CP; Perlman S; Hertweck SP
J Pediatr Adolesc Gynecol; 2004 Feb; 17(1):17-21. PubMed ID: 15010034
[TBL] [Abstract][Full Text] [Related]
15. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.
Sanches L; Marchi NM; Castro S; Juliato CT; Villarroel M; Bahamondes L
Contraception; 2008 Nov; 78(5):365-9. PubMed ID: 18929732
[TBL] [Abstract][Full Text] [Related]
16. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception.
Wanichsetakul P; Kamudhamas A; Watanaruangkovit P; Siripakarn Y; Visutakul P
Contraception; 2002 Jun; 65(6):407-10. PubMed ID: 12127638
[TBL] [Abstract][Full Text] [Related]
18. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
[TBL] [Abstract][Full Text] [Related]
19. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.
Viola AS; Castro S; Marchi NM; Bahamondes MV; Viola CF; Bahamondes L
Contraception; 2011 Aug; 84(2):122-7. PubMed ID: 21757052
[TBL] [Abstract][Full Text] [Related]
20. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women.
Lizarelli PM; Martins WP; Vieira CS; Soares GM; Franceschini SA; Ferriani RA; Patta MC
Contraception; 2009 Jan; 79(1):35-40. PubMed ID: 19041439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
